Quicker Remission With Tofacitinib vs Vedolizumab in Ulcerative Colitis: Study

Tofacitinib achieves higher clinical and biochemical remission rates than vedolizumab for patients with anti-TNF-exposed ulcerative colitis, although the effect diminishes over time, say Dutch scientists.
Medscape Medical News
Tofacitinib achieves higher clinical and biochemical remission rates than vedolizumab for patients with anti-TNF-exposed ulcerative colitis, although the effect diminishes over time, say Dutch scientists.
Medscape Medical News